COMPANION-002: A Randomized Phase II/III Trial of Tovecimig Plus Paclitaxel Versus Paclitaxel Alone as a Second-Line Therapy in Patients With Advanced Biliary Tract Cancer
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Purpose Patients with previously treated biliary tract cancer (BTC) have a short median overall survival (OS) and few treatment options. Tovecimig, a bispecific antibody to delta-like ligand-4 and vascular endothelial growth factor (VEGF)-A, was evaluated in combination with paclitaxel in COMPANION-002, a randomized phase II/III study in pretreated patients with advanced BTC. Patients and Methods Patients with advanced BTC with one prior systemic therapy were randomly assigned to paclitaxel (80 mg/m 2 ; once weekly on days 1, 8 and 15) with or without tovecimig (10 mg/kg; once every 2 weeks on days 1 and 15) in each 28-day cycle. The primary end point was RECIST v1.1-defined overall response rate (ORR) as assessed by blinded independent central review (BICR). Secondary end points included progression-free survival (PFS) and OS. Crossover from the paclitaxel control arm to tovecimig plus paclitaxel was permitted following BICR-confirmed progression. Results A total of 168 patients were randomly assigned 2:1 to tovecimig + paclitaxel (n = 111) or paclitaxel alone (n = 57). Tovecimig + paclitaxel significantly improved BICR-assessed ORR (18.0% v 5.3%; P = .0228) and PFS (4.7 v 2.6 months; hazard ratio [HR], 0.44; P < .0001). Among 31 patients (54%) who crossed over, postprogression PFS (time from crossover to subsequent second progression) exceeded initial PFS (PFS from random assignment to initial progression on paclitaxel; 3.5 v 1.9 months; HR, 0.40; P = .0035). Overall, 142 patients (85%) received tovecimig; no difference in OS was observed (HR, 1.05; P = .779). The most common treatment-emergent adverse events (TEAEs) with tovecimig + paclitaxel were hypertension (69.4%) and fatigue (66.7%). Grade ≥3 TEAEs occurred in 93.5% and 64.2% of patients treated with tovecimig + paclitaxel and paclitaxel alone, respectively. Conclusion Tovecimig combined with paclitaxel significantly improved ORR and PFS versus paclitaxel alone as second-line therapy for patients with BTC.
Source: Journal of Clinical Oncology
DOI: 10.1200/jco-26-02188
Authors: Nilofer S. Azad, Z. Ian Hu, Priyadarshini Pathak, Ilyas Sahin, Olivia Aranha, Renuka Iyer, Gregory M. Heestand, Chih-Yi Liao, Howard S. Hochster, Aparna Kalyan, Anthony El-Khoueiry, Andrew Scott Paulson, Robin Kate Kelley, Mitesh J. Borad, Lipika Goyal, Cynthia A. Sirard, Thomas J. Schuetz, Milind Javle
Institutions: Sidney Kimmel Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, University of Florida Health, Washington University in St. Louis, Roswell Park Comprehensive Cancer Center, Stanford Medicine, Stanford University, University of Chicago Medical Center, Rutgers Cancer Institute, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, USC Norris Comprehensive Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Mayo Clinic in Arizona, Compass Therapeutics, Inc. (United States)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7223440479
